Cosmos Health Inc. (COSM)
USD 0.34
(-2.95%)
USD 0.34
(-2.95%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.06 Million USD | -123.96% |
| 2022 | -8.9 Million USD | -129.59% |
| 2021 | -3.81 Million USD | -229.66% |
| 2020 | 3.18 Million USD | 753.87% |
| 2019 | -988.58 Thousand USD | 131.98% |
| 2018 | -2.19 Million USD | 60.14% |
| 2017 | -4.54 Million USD | -1320.78% |
| 2016 | -384.76 Thousand USD | 52.8% |
| 2015 | -6.59 Million USD | -106.12% |
| 2014 | 7.12 Million USD | 2368.1% |
| 2013 | 288.71 Thousand USD | 63553.19% |
| 2012 | -22.47 Thousand USD | 99.73% |
| 2011 | -168.41 Thousand USD | 95.55% |
| 2010 | -3.78 Million USD | -82233.24% |
| 2009 | -4600.00 USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.21 Million USD | 89.62% |
| 2024 Q2 | -2.18 Million USD | -40.41% |
| 2023 Q3 | -2.64 Million USD | -18.97% |
| 2023 FY | - USD | -123.96% |
| 2023 Q1 | -2.35 Million USD | 75.35% |
| 2023 Q2 | -2.22 Million USD | 5.82% |
| 2023 Q4 | -13.45 Million USD | -408.76% |
| 2022 Q1 | 364.88 Thousand USD | 515.91% |
| 2022 Q3 | -236.66 Thousand USD | -792.61% |
| 2022 Q4 | -9.57 Million USD | -3944.14% |
| 2022 FY | - USD | -129.59% |
| 2022 Q2 | 34.17 Thousand USD | -90.64% |
| 2021 Q2 | -1.3 Million USD | 27.45% |
| 2021 Q3 | -928.83 Thousand USD | 28.96% |
| 2021 Q4 | -87.73 Thousand USD | 90.55% |
| 2021 FY | - USD | -229.66% |
| 2021 Q1 | -1.8 Million USD | -468.69% |
| 2020 Q1 | 314.13 Thousand USD | -56.17% |
| 2020 Q4 | 488.82 Thousand USD | -60.67% |
| 2020 Q3 | 1.24 Million USD | 9.36% |
| 2020 FY | - USD | 753.87% |
| 2020 Q2 | 1.13 Million USD | 261.78% |
| 2019 Q2 | -52.58 Thousand USD | -15.87% |
| 2019 Q4 | 716.73 Thousand USD | 1819.57% |
| 2019 FY | - USD | 131.98% |
| 2019 Q1 | -45.38 Thousand USD | 95.44% |
| 2019 Q3 | -41.68 Thousand USD | 20.73% |
| 2018 Q2 | -74.8 Thousand USD | 48.24% |
| 2018 Q3 | 49.82 Thousand USD | 166.61% |
| 2018 Q4 | -995.9 Thousand USD | -2098.73% |
| 2018 FY | - USD | 60.14% |
| 2018 Q1 | -144.53 Thousand USD | 3.44% |
| 2017 Q1 | -41.45 Thousand USD | 23.01% |
| 2017 FY | - USD | -1320.78% |
| 2017 Q4 | -149.67 Thousand USD | -1705.97% |
| 2017 Q3 | 9320.00 USD | 101.18% |
| 2017 Q2 | -792.33 Thousand USD | -1811.45% |
| 2016 Q2 | -84.94 Thousand USD | -127.22% |
| 2016 Q4 | -53.84 Thousand USD | -88.61% |
| 2016 Q3 | -28.54 Thousand USD | 66.39% |
| 2016 FY | - USD | 52.8% |
| 2016 Q1 | -37.38 Thousand USD | 99.41% |
| 2015 Q2 | -109.56 Thousand USD | -31.26% |
| 2015 Q1 | -83.46 Thousand USD | 65.77% |
| 2015 FY | - USD | -106.12% |
| 2015 Q4 | -6.33 Million USD | -9189.69% |
| 2015 Q3 | -68.14 Thousand USD | 37.8% |
| 2014 Q2 | 1.06 Million USD | 50.58% |
| 2014 Q1 | 707.88 Thousand USD | -17.86% |
| 2014 Q3 | 5.58 Million USD | 424.09% |
| 2014 Q4 | -243.83 Thousand USD | -104.36% |
| 2014 FY | - USD | 2368.1% |
| 2013 Q2 | -42 Thousand USD | 25.02% |
| 2013 FY | - USD | 63553.19% |
| 2013 Q1 | -56.02 Thousand USD | 50.26% |
| 2013 Q3 | -79.34 Thousand USD | -88.89% |
| 2013 Q4 | 861.77 Thousand USD | 1186.16% |
| 2012 Q2 | -59.45 Thousand USD | -12.55% |
| 2012 Q1 | -52.82 Thousand USD | 3.59% |
| 2012 Q4 | -112.64 Thousand USD | 10.69% |
| 2012 Q3 | -126.12 Thousand USD | -112.12% |
| 2012 FY | - USD | 99.73% |
| 2011 Q3 | -159.78 Thousand USD | -161.04% |
| 2011 Q2 | -61.21 Thousand USD | 29.8% |
| 2011 Q4 | -54.79 Thousand USD | 65.71% |
| 2011 Q1 | -87.19 Thousand USD | -660.55% |
| 2011 FY | - USD | 95.55% |
| 2010 Q1 | -21.08 Thousand USD | -167.01% |
| 2010 FY | - USD | -82233.24% |
| 2010 Q2 | -3.71 Million USD | -17538.85% |
| 2010 Q3 | -8545.00 USD | 99.77% |
| 2010 Q4 | -11.46 Thousand USD | -34.16% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | -7897.00 USD | 79.76% |
| 2009 Q3 | -39.01 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bright Green Corporation | - USD | Infinity% |
| Alpha Teknova, Inc. | -25.53 Million USD | 33.193% |
| ANI Pharmaceuticals, Inc. | 109.32 Million USD | 115.607% |
| Aquestive Therapeutics, Inc. | 1.18 Million USD | 1543.468% |
| Collegium Pharmaceutical, Inc. | 308.32 Million USD | 105.534% |
| Journey Medical Corporation | 1.92 Million USD | 988.173% |
| Embecta Corp. | 245.4 Million USD | 106.953% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | 88.634% |
| Dynavax Technologies Corporation | 9.66 Million USD | 276.514% |
| Intra-Cellular Therapies, Inc. | -158.85 Million USD | 89.259% |
| Pacira BioSciences, Inc. | 162.89 Million USD | 110.474% |
| PainReform Ltd. | -9.56 Million USD | -78.303% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -346.128% |
| Sunshine Biopharma, Inc. | -3.82 Million USD | -346.128% |
| SCYNEXIS, Inc. | 73.47 Million USD | 123.22% |
| Safety Shot Inc | -12.18 Million USD | -40.021% |
| China SXT Pharmaceuticals, Inc. | -2.35 Million USD | -625.722% |
| Procaps Group, S.A. | 104.02 Million USD | 116.401% |
| Theratechnologies Inc. | -10.31 Million USD | -65.443% |
| Harrow Health, Inc. | 9.72 Million USD | 275.479% |
| Sonoma Pharmaceuticals, Inc. | -4.52 Million USD | -277.056% |
| Biofrontera Inc. | -18.45 Million USD | 7.539% |
| DURECT Corporation | -24.68 Million USD | 30.879% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 117.364% |
| Cronos Group Inc. | -72.14 Million USD | 76.352% |
| OptiNose, Inc. | -15.55 Million USD | -9.701% |
| Ironwood Pharmaceuticals, Inc. | -924.86 Million USD | 98.155% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | 52.714% |
| RedHill Biopharma Ltd. | 26.26 Million USD | 164.957% |
| Organogenesis Holdings Inc. | 36.03 Million USD | 147.353% |
| Guardion Health Sciences, Inc. | -3.92 Million USD | -334.989% |
| Cumberland Pharmaceuticals Inc. | -710.85 Thousand USD | -2300.197% |
| Radius Health, Inc. | 38.31 Million USD | 144.536% |
| Universe Pharmaceuticals INC | -3.21 Million USD | -430.682% |
| ProPhase Labs, Inc. | -14.82 Million USD | -15.072% |
| Phibro Animal Health Corporation | 84.6 Million USD | 120.166% |
| Procaps Group S.A. | 104.02 Million USD | 116.401% |
| Alvotech | -484.86 Million USD | 96.481% |
| TherapeuticsMD, Inc. | -8.4 Million USD | -103.092% |
| Viatris Inc. | 3.51 Billion USD | 100.485% |
| Rockwell Medical, Inc. | -4.69 Million USD | -263.481% |
| Aytu BioPharma, Inc. | -1.01 Million USD | -1585.948% |
| SIGA Technologies, Inc. | 84.15 Million USD | 120.273% |
| Tilray Brands, Inc. | -72.84 Million USD | 76.577% |
| Lifecore Biomedical, Inc. | 812 Thousand USD | 2201.207% |
| Shineco, Inc. | -26.55 Million USD | 35.747% |
| PetIQ, Inc. | 81.48 Million USD | 120.938% |
| Regencell Bioscience Holdings Limited | -3.61 Million USD | -371.629% |
| Incannex Healthcare Limited | -18.5 Million USD | 7.794% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 104.1% |
| Alimera Sciences, Inc. | 7.27 Million USD | 334.494% |
| Silver Spike Investment Corp. | 7.34 Million USD | 332.446% |
| Assertio Holdings, Inc. | -222.44 Million USD | 92.33% |
| Shuttle Pharmaceuticals Holdings, Inc. | -3.99 Million USD | -327.544% |
| Petros Pharmaceuticals, Inc. | -4.21 Million USD | -305.088% |
| Clever Leaves Holdings Inc. | -16.8 Million USD | -1.534% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 14.822% |
| Avadel Pharmaceuticals plc | -149.12 Million USD | 88.559% |
| Hempacco Co., Inc. | -12.77 Million USD | -33.574% |
| Talphera, Inc. | -9.84 Million USD | -73.357% |
| Alvotech | -484.86 Million USD | 96.481% |
| Eagle Pharmaceuticals, Inc. | 77.5 Million USD | 122.015% |
| Lantheus Holdings, Inc. | 491 Million USD | 103.475% |
| Currenc Group, Inc. | -1.9 Million USD | -797.718% |
| Kamada Ltd. | 21.53 Million USD | 179.232% |
| Indivior PLC | 66 Million USD | 125.851% |
| Evoke Pharma, Inc. | -7.29 Million USD | -133.97% |
| Flora Growth Corp. | -45.87 Million USD | 62.804% |
| Cyclo Therapeutics, Inc. | -20.03 Million USD | 14.822% |
| Evolus, Inc. | -41.81 Million USD | 59.192% |
| HUTCHMED (China) Limited | 25.52 Million USD | 166.836% |
| Amphastar Pharmaceuticals, Inc. | 241.46 Million USD | 107.066% |
| Akanda Corp. | -27.73 Million USD | 38.484% |